Scarica l'app Stockscreener
14.93
2.26%
0.33
Pre-mercato:
14.91
-0.02
-0.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SDGR Giù?
Forum
Previsione
Precedente Chiudi:
$14.60
Aprire:
$14.69
Volume 24 ore:
1.19M
Relative Volume:
0.89
Capitalizzazione di mercato:
$1.12B
Reddito:
$254.91M
Utile/perdita netta:
$-103.48M
Rapporto P/E:
-10.64
EPS:
-1.4036
Flusso di cassa netto:
$-148.35M
1 W Prestazione:
+2.82%
1M Prestazione:
+24.94%
6M Prestazione:
-16.78%
1 anno Prestazione:
-29.58%
Intervallo 1D:
$14.52
$15.22
Intervallo di 1 settimana:
$13.90
$15.22
Portata 52W:
$10.95
$23.75
Schrodinger Inc Stock (SDGR) Company Profile
Nome
Schrodinger Inc
Settore
Industria
Telefono
503-299-1150
Indirizzo
1540 BROADWAY, NEW YORK, NY
Compare SDGR vs VEEV, BTSG, TEM, HQY, HNGE
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SDGR
Schrodinger Inc
|
14.93 | 1.09B | 254.91M | -103.48M | -148.35M | -1.4036 |
VEEV
Veeva Systems Inc
|
163.38 | 26.34B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
64.14 | 12.58B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
50.56 | 9.39B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
85.66 | 7.27B | 1.34B | 230.70M | 440.96M | 2.6695 |
HNGE
Hinge Health Inc
|
67.81 | 5.29B | 646.34M | -512.40M | 202.76M | -6.6871 |
Schrodinger Inc Stock (SDGR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-15 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-09-30 | Iniziato | Goldman | Neutral |
| 2025-08-15 | Downgrade | Citigroup | Buy → Neutral |
| 2025-08-14 | Iniziato | Barclays | Overweight |
| 2025-07-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-07-02 | Iniziato | Leerink Partners | Outperform |
| 2023-12-05 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2023-05-05 | Ripresa | Piper Sandler | Overweight |
| 2022-12-19 | Iniziato | Goldman | Neutral |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2021-11-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-19 | Iniziato | Piper Sandler | Overweight |
| 2021-11-11 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-10-13 | Iniziato | Berenberg | Buy |
| 2021-09-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-05-25 | Iniziato | Craig Hallum | Buy |
| 2020-11-23 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-10-12 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-03-02 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-02 | Iniziato | Jefferies | Hold |
| 2020-03-02 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Schrodinger Inc Borsa (SDGR) Ultime notizie
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates - MSN
SDGR Q1 2026 Earnings: EPS Misses Estimates as Company Focuses on Pipeline ProgressEarnings Acceleration Picks - The League of Women Voters of Texas
Schrödinger Finalizes Transition Terms for Former Commercial Chief - The Globe and Mail
Schrodinger finalizes separation agreement with former chief commercial officer - Investing.com
Schrodinger separation of Mannix Aklian as Chief Commercial Officer confirmed - TradingView
Severance package for ex-commercial chief at Schrödinger (NASDAQ: SDGR) - Stock Titan
(SDGR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Schrödinger’s Call Review: The Power of a Final Call - DualShockers
10 Top Tech Companies in Munich - Built In
Recursion vs. Schrodinger: Comparing Biotech and Software Drug Discovery Strategies in 2026News and Statistics - IndexBox
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Does Schrödinger (SDGR) Changing Its CCO While Reaffirming Guidance Recast Its Commercial Playbook? - simplywall.st
Schrodinger Inc stock (US80655G1067): shares extend late-May rebound on Nasdaq - AD HOC NEWS
Schrödinger, Inc. Hits Day High with Strong 7.34% Intraday Surge - MarketsMojo
Schrödinger, Inc. Hits Day High with Strong Intraday Performance, Up 7.39% - Markets Mojo
Companies Like Schrödinger (NASDAQ:SDGR) Are In A Position To Invest In Growth - Moomoo
Another Indie Matched Mina The Hollower's Review Scores This Week And No One Noticed - TheGamer
A Look at Schrodinger Inc (SDGR) After 6.9% Gain -- GF Value $26 - GuruFocus
SDGR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Schrodinger Inc stock (US80655G1067): shares steady after May gains on Nasdaq - AD HOC NEWS
Schrödinger slides after early-stage trial data for cancer therapy - MSN
(SDGR) Risk Channels and Responsive Allocation - Stock Traders Daily
How The Schrödinger (SDGR) Investment Story Is Shifting As Analysts Reset Price Targets - Yahoo Finance
Stephens Investment Management Group LLC's Schrodinger Inc(SDGR) Holding History - GuruFocus
Schrodinger (SDGR) Issues Stock Options and RSUs to New Employees - GuruFocus
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - pharmiweb.com
Schrodinger reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Schrodinger Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Schrödinger Announces Leadership Change Amid Maintained 2026 Outlook - TipRanks
Schrödinger, Inc. Reaffirms Earnings Guidance for the Second Quarter Ending June 30, 2026 and Fiscal Year Ending December 31, 2026 - marketscreener.com
Leadership change at Schrödinger (NASDAQ: SDGR) as CCO departs and outlook held - Stock Titan
My Top 3 Biotech Stocks for May 2026 - Yahoo Finance
Schrödinger Balances Growth and Losses in Earnings Call - TipRanks
SDGR: Improved funding and tech adoption are accelerating drug discovery and portfolio growth - TradingView
Schrodinger Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Schrodinger : SDGR - 24/7 Wall St.
Cheminformatics Market Size, Share | Growth Forecast [2034] - Fortune Business Insights
Schrodinger stock (US80655G1067): AI-powered drug discovery story after latest earnings - AD HOC NEWS
Rubric Capital and David Rosen disclose 9.28% position in Schrodinger (SDGR) - Stock Titan
(SDGR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
SDGR Maintained by Morgan Stanley -- Price Target Lowered to $17 - GuruFocus
Morgan Stanley Maintains Schrodinger(SDGR.US) With Hold Rating, Cuts Target Price to $17 - Moomoo
Morgan Stanley Lowers Price Target on Schrodinger to $17 From $19, Keeps Equalweight Rating - marketscreener.com
Schrodinger, Inc. Stock 12‑Month Price Target Cut to $20.88, Implies 64% Upside - TradingView
SDGR: Hosted revenue jumps to 34% as broad-based growth and new products drive positive momentum - TradingView
SDGR Stock Price, Quote & Chart | SCHRODINGER INC (NASDAQ:SDGR) - ChartMill
Evogene to Present at the 24th Schrödinger European User Group Meeting - PR Newswire
TradingKey - TradingKey
UBS Group AG Buys 489,059 Shares of Schrodinger, Inc. $SDGR - MarketBeat
Schrodinger Inc Azioni (SDGR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Schrodinger Inc Azioni (SDGR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Farid Ramy | President & CEO |
Apr 17 '26 |
Option Exercise |
3.07 |
117,527 |
360,808 |
405,351 |
| Farid Ramy | President & CEO |
Apr 16 '26 |
Option Exercise |
3.07 |
43,000 |
132,010 |
373,824 |
| Farid Ramy | President & CEO |
Apr 16 '26 |
Sale |
12.33 |
43,000 |
530,233 |
330,824 |
| Farid Ramy | President & CEO |
Apr 17 '26 |
Sale |
12.21 |
43,000 |
524,944 |
330,824 |
| Jain Rachit | EVP & CFO |
Apr 16 '26 |
Sale |
12.75 |
844 |
10,758 |
51,752 |
2.22%
0.92%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):